Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KQB548 in Advanced Solid Malignancies With a KRAS G12D Mutation
NCT07207707Phase 1Recruiting
- Sponsor
- Kumquat Biosciences
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KQB548 in solid tumor, pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and 1 more, sponsored by Kumquat Biosciences. Primary endpoint: Safety, Tolerability, MTD/MAD and/or RDE in the Study Population up to 30 months. Started Sep 2025; status: recruiting.
02
Drugs
KQB548
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07207707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07207707.